<DOC>
	<DOCNO>NCT01537432</DOCNO>
	<brief_summary>This study design evaluate proportion patient achieve reversal chronic plaque psoriasis week 4 12 follow multiple dos secukinumab administer subcutaneously ( sc ) compare placebo . Starting week 13 , patient receive multiple dos secukinumab week 52 study long term effect secukinumab . Clinical endpoint include biomarker assessment , PASI , IGA DLQI compare well understand , secukinumab may effective psoriasis patient .</brief_summary>
	<brief_title>Multiple-dose Regimen Study Assess Effect 12 Months Secukinumab Treatment Skin Response Biomarkers Psoriasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<criteria>Inclusion criterion : Chronic plaquetype psoriasis diagnose least 6 month Moderate severe psoriasis define : PASI score ≥12 , IGA score ≥3 , BSA ( body surface area ) affect plaquetype psoriasis ≥10 % Chronic plaquetype psoriasis consider inadequately control : topical treatment and/or ; phototherapy and/or previous systemic therapy Exclusion criterion : Forms psoriasis chronic plaquetype Evidence skin condition time screen visit ( e.g. , eczema ) would interfere evaluation effect investigational product psoriasis History evidence active tuberculosis evidence latent tuberculosis ( infection like HepatitisC/B ) , malignancy ; active know use immunosuppressive drug ( eg : AIDs , RA , organ rejection etc . ) screen visit Pregnant nursing ( lactate ) woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Psoriasis , Plaque-type psoriasis</keyword>
	<keyword>Plaque</keyword>
	<keyword>Secukinumab</keyword>
	<keyword>AIN457A</keyword>
	<keyword>PASI</keyword>
	<keyword>DLQI</keyword>
	<keyword>IGA</keyword>
</DOC>